Search companies

Live

Tuesday, 17 November 2026 · 577 Summaries Today

S&P/ASX 200 · 8,883.20 (-1.79%)

Alterity Advances ATH434 Phase 3 Preparations After FDA Trial Design Agreement

ATH: $0.265 +1.92% · MC: $57M

Alterity Therapeutics says FDA meeting minutes confirmed agreement on the proposed Phase 3 trial design for ATH434 in multiple system atrophy, and operational preparations are underway. The FDA indicated that a single pivotal trial plus confirmatory evidence could support approval, although approval is not assured. Alterity is evaluating funding and partnering alternatives and ended the quarter with approximately $41 million in cash, including a tax refund and proceeds from option exercises. A new US patent for ATH434 extends protection to 2045.

Source announcements: 2026-10-30 11:39 to 2026-10-30 11:39 Sydney time
Story updated 2026-10-30 12:23 Sydney time
SourcesQuarterly Activities/Appendix 4C Cash Flow Report
Comments